Reliability and crew safety assessment for a solid rocket Booster/J-2S launcher

被引:0
|
作者
Fragola, Joseph
Baum, J. D.
Sauvageau, Don
Horowitz, Scott J.
机构
来源
2006 Proceedings - Annual Reliability and Maintainability Symposium, Vols 1 and 2 | 2006年
关键词
crew exploration vehicle; NASA; expendable launch vehicle; solid rocket booster;
D O I
暂无
中图分类号
TP31 [计算机软件];
学科分类号
081202 ; 0835 ;
摘要
NASA's Exploration Mission Directorate is currently developing plans to carry out the President's Vision for Space Exploration. This plan includes retiring the Space Shuttle by 2010 and developing the Crew Exploration Vehicle (CEV) to transport astronauts to/from Low Earth Orbit (LEO). There are several alternatives to launch the CEV, including Evolved Expendable Launch Vehicles (EELVs) and launch vehicles derived from new and existing propulsion elements. In May, 2003 the astronaut office made clear its position on the need and feasibility of improving crew safety for future NASA manned missions indicating their "consensus that an order of magnitude reduction in the risk of human life during ascent, compared to the Space Shuttle, is both achievable with current technology and consistent with NASA's focus on steadily improving rocket reliability". The astronaut office set a goal for the Probability of Loss of Crew (P-LOC) to be better than 1 in 1,000. This paper documents the evolution of a launch vehicle deign to meet the needs for launching the crew aboard a CEV. The process implemented and the results obtained from, a top-down evaluation performed on the proposed design are presented.
引用
收藏
页码:545 / 550
页数:6
相关论文
共 50 条
  • [41] Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial
    Le Gars, Mathieu
    Sadoff, Jerald
    Cardenas, Vicky
    Heerwegh, Dirk
    Tesfaye, Fisseha
    Van Roey, Griet
    Spicer, Colleen
    Matias, Samantha Santoro
    Crayne, Olivia
    Kamphuis, Tobias
    Struyf, Frank
    Schuitemaker, Hanneke
    Douoguih, Macaya
    VACCINE, 2024, 42 (19) : 3938 - 3952
  • [42] Product-operator formalism in I>=½ and S>=3/2 J-coupled nuclear spins: application to J assessment via SEDOR experiment
    Capuani, S.
    De Luca, F.
    Maraviglia, B.
    Journal of Chemical Physics, 1998, 109 (16):
  • [43] Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2. Safety Assessment and Toxicologic Pathology.
    Haschek-Hock, W. M.
    Rousseaux, C. G.
    Wallig, M. A.
    Bolon., B.
    ANTICANCER RESEARCH, 2023, 43 (11)
  • [44] Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
    Wanchaijiraboon, Passakorn
    Sainamthip, Panot
    Teeyapun, Nattaya
    Luangdilok, Sutima
    Poovorawan, Yong
    Wanlapakorn, Nasamon
    Tanasanvimon, Suebpong
    Sriuranpong, Virote
    Susiriwatananont, Thiti
    Zungsontiporn, Nicha
    Pakvisal, Nussara
    VACCINES, 2023, 11 (02)
  • [45] Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer's disease model
    Parikh, Ankit
    Kathawala, Krishna
    Li, Jintao
    Chen, Chi
    Shan, Zhengnan
    Cao, Xia
    Wang, Yan-Jiang
    Garg, Sanjay
    Zhou, Xin-Fu
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 2111 - 2128
  • [46] Safety, Health and Environment (SHE) and Management of Change (MOC) Assessment Methodology applied as a web-based S2S tool
    Nivolianitou, Zoe
    Schabel, Jari
    Adolph, Andrei
    RISK, RELIABILITY AND SOCIETAL SAFETY, VOLS 1-3: VOL 1: SPECIALISATION TOPICS; VOL 2: THEMATIC TOPICS; VOL 3: APPLICATIONS TOPICS, 2007, : 1909 - +
  • [47] Safety Assessment of AAV2-hGDNF Administered Via Intracerebral Injection in Rats for Treatment of Parkinson's Disease
    Terse, Pramod S.
    Kells, Adrian P.
    Noker, Patricia
    Wright, J. Fraser
    Bankiewicz, Krystof S.
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2021, 40 (01) : 4 - 14
  • [48] Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study
    Shinkai, Masaharu
    Sonoyama, Takuhiro
    Kamitani, Akari
    Shibata, Risa Yokokawa
    Seki, Naomi M.
    Omoto, Shinya
    Shinoda, Masahiro
    Sato, Takashi
    Ishii, Naoki
    Igarashi, Kenji
    Ariyasu, Mari
    VACCINE, 2022, 40 (32) : 4328 - 4333
  • [49] Immunogenicity and Safety of Half-Dose Heterologous mRNA-1273 Booster Vaccination for Adults Primed with the CoronaVac® and ChAdOx1-S Vaccines for SARS-CoV-2
    Putri, Nina Dwi
    Zhafira, Aqila Sakina
    Wicaksana, Pratama
    Sinto, Robert
    Hanafi, Gryselda
    Wiyono, Lowilius
    Prayitno, Ari
    Karyanti, Mulya Rahma
    Naibaho, Murni Luciana
    Febrina, Febrina
    Sukandar, Hadyana
    Setiawaty, Vivi
    Mursinah, Mursinah
    Putra, Ahmat Rediansya
    Wibowo, Heri
    Sundoro, Julitasari
    Satari, Hindra Irawan
    Oktavia, Dwi
    Multihartina, Pretty
    Harbuwono, Dante Saksono
    Hadinegoro, Sri Rezeki
    VACCINES, 2024, 12 (04)
  • [50] Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents
    Vesikari, Timo
    Brzostek, Jerzy
    Ahonen, Anitta
    Paassilta, Marita
    Majda-Stanislawska, Ewa
    Szenborn, Leszek
    Virta, Miia
    Clifford, Robert
    Jackowska, Teresa
    Kimmel, Murray
    Bindi, Ilaria
    Keshavan, Pavitra
    Pedotti, Paola
    Toneatto, Daniela
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (11) : 4689 - 4700